| Population 2014 |
11 million |
| | |
| | | | | | | |
| Estimates of TB burden * 2014 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
2.5 |
(1.8–3.3) |
23 |
(17–30) |
| Mortality (HIV+TB only) |
0.69 |
(0.57–0.82) |
6.4 |
(5.3–7.5) |
| Prevalence (includes HIV+TB) |
21 |
(11–34) |
195 |
(105–313) |
| Incidence (includes HIV+TB) |
14 |
(13–15) |
126 |
(116–136) |
| Incidence (HIV+TB only) |
1.9 |
(1.6–2.1) |
17 |
(15–20) |
| |
|
|
|
|
| Case detection, all forms (%) |
53 |
(49–58) |
|
|
| | |
| | | | | | | |
| Estimates of MDR-TB burden * 2014 |
|
New |
|
Retreatment |
| % of TB cases with MDR-TB |
2.2 |
(0.3–4.1) |
11 |
(6.2–16) |
MDR-TB cases among notified pulmonary
TB cases |
110 |
(15–200) |
32 |
(18–45) |
| | |
| | | | | | | |
| TB case notifications 2014 |
New ** |
Relapse |
| Pulmonary, bacteriologically confirmed |
4 265 |
|
206 |
| Pulmonary, clinically diagnosed |
653 |
|
0 |
| Extrapulmonary |
2 102 |
|
0 |
| |
|
|
|
| Total new and relapse |
7 226 |
|
|
| Previously treated, excluding relapses |
83 |
|
|
| Total cases notified |
7 309 |
|
|
| | |
| | | | | | | |
| Among 7 020 new cases: | | | | | | |
| 528 (8%) cases aged under 15 years; male:female ratio: 1.8 | | | | |
| | | | | | | |
| Reported cases of RR-/MDR-TB 2014 |
New |
Retreatment |
Total ** |
| Cases tested for RR-/MDR-TB |
289 (7%) |
60 (21%) |
289 |
| Laboratory-confirmed RR-/MDR-TB cases |
|
|
48 |
| Patients started on MDR-TB treatment *** |
|
|
49 |
| | |
| | | | | | | |
| TB/HIV 2014 |
Number |
(%) |
| TB patients with known HIV status |
6 654 |
(91) |
| HIV-positive TB patients |
901 |
(14) |
| HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) |
873 |
(97) |
| HIV-positive TB patients on antiretroviral therapy (ART) |
611 |
(68) |
| HIV-positive people screened for TB |
976 |
|
| HIV-positive people provided with IPT |
|
|
| | |
| | | | | | | |
| Treatment success rate and cohort size |
(%) |
Cohort |
| New and relapse cases registered in 2013 |
(91) |
7 547 |
| Previously treated cases, excluding relapse, registered in 2013 |
(84) |
80 |
| HIV-positive TB cases, all types, registered in 2013 |
(87) |
977 |
| RR-/MDR-TB cases started on second-line treatment in 2012 |
(92) |
36 |
| XDR-TB cases started on second-line treatment in 2012 |
|
0 |
| | |
| | | | | | | |
| Laboratories 2014 |
|
| Smear (per 100 000 population) |
1.6 |
| Culture (per 5 million population) |
0.5 |
| Drug susceptibility testing (per 5 million population) |
0.5 |
| Sites performing Xpert MTB/RIF |
1 |
| Is second-line drug susceptibility testing available? |
Yes, in and outside
country |
| | |
| | | | | | | |
| Financing TB control 2015 |
|
| National TB programme budget (US$ millions) |
<1 |
| % Funded domestically |
0% |
| % Funded internationally |
100% |
| % Unfunded |
0% |
| | |
| | | | | | | |
| * Ranges represent uncertainty intervals | | | | | |
| ** Includes cases with unknown previous TB treatment history | | | |
| *** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having | |
| RR-/MDR-TB | | | | | | | |
| | | | | | | |